Please note this trial is now closed to recruitment. The trial recruited women diagnosed with ovarian cancer who were not responding to platinum treatment and were considering a further therapy. You can find more information in the ‘Information for Patients’ box on the bottom of this page.
Results have now been published for this trial in the British Journal of Cancer: Results of a randomised Phase II trial of olaparib, chemotherapy of olaparib and cediranib in patients with platinum-resistant ovarian cancer
A lay summary of the trial results can be found on the CRUK website using the following link: https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-different-treatments-for-women-who-have-ovarian-cancer-octova
We have met our recruitment target and the study is now closed to recruitment. A big thanks to all who took part and those still involved with the study.
Chief Investigator: Shibani Nicum
Sponsor: University of Oxford
Funder: AstraZeneca
Endorsed by: Cancer Research UK
EudraCT Number: 2016-000559-28
Ethics Reference: 16/LO/2150
You can find more information about the trial eligibility criteria here.
OCTOVA is a trial for women with ovarian cancer that are resistant to platinum-based chemotherapy. You can find more information on the trial here.
